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ABSTRACT: Proteasome inhibitors are established therapeutic agents for the treatment of hematological cancers, as are
anthracyclines such as doxorubicin. We here present a new drug targeting approach that combines both drug classes into a single
molecule. Doxorubicin was conjugated to an immunoproteasome-selective inhibitor via light-cleavable linkers, yielding peptide
epoxyketone−doxorubicin prodrugs that remained selective and active toward immunoproteasomes. Upon cellular uptake and
immunoproteasome inhibition, doxorubicin is released from the immunoproteasome inhibitor through photoirradiation. Multiple
myeloma cells in this way take a double hit: immunoproteasome inhibition and doxorubicin-induced toxicity. Our strategy, which
entails targeting of a cytotoxic agent, through a covalent enzyme inhibitor that is detrimental to tumor tissue in its own right, may
find use in the search for improved anticancer drugs.
The selective delivery of cytotoxic agents to tumor cells isan important strategy to increase efficacy and to reduce
side effects.1−3 By rendering the drug inactive and attaching it
to a targeting elementoften through a cleavable linker
toxicity is controlled and drugs can be used at higher doses.
There are multiple ways to dissociate the drug from the carrier:
release through local (bio)chemical conditions, such as the
activity of specific enzymes,4 pH,5 or changes in redox
potential,6,7 offers one approach. Alternatively, exogenous
triggers can be used to initiate release of the drug from the
construct, including bioorthogonal click-to-release8−10 and
photochemical deprotection.11−13 In current strategies, the
cytotoxic agents are normally conjugated to antibodies,
peptides,12 or carbohydrates13 with high affinity and selectivity
for cell surface proteins residing exclusively or predominantly
(in comparison to healthy tissue) on tumor cells. It is,
however, known that many hematological malignancies are
also marked by the upregulation of very specific intracellular
enzyme activities. We hypothesized that targeting such enzyme
activities through covalent and irreversible inhibitors carrying a
cytotoxic agent would present an alternative to the above cell-
surface-targeting conjugation strategies (Figure 1). In such a
scheme, the conjugate is allowed to accumulate in malignant
cells with high enzyme activity, after which the cytotoxic cargo
is released through one of the aforementioned exogenous
triggers to fulfill its function.
Multiple myeloma poses such a target. It is a hematological
malignancy characterized by a distinct protease activity profile.
It expresses predominantly immunoproteasomes rather than
constitutive proteasomes, unlike healthy B-cells, which have
both proteasome types at about equal amounts.14 Multiple
myeloma patients are currently treated with covalent and
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Figure 1. Structure of photocleavable doxorubicin−proteasome
inhibitor conjugate (1), and the schematic strategy for dual targeting.
First, the probe is targeted to cells containing immunoproteasome
core particles. Then, after photocleavage, doxorubicin is released,
leading to DNA breakage and histone eviction, leading to cell death.
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irreversible proteasome inhibitors, such as bortezomib and
carfilzomib (CFZ). These agents block both constitutive
proteasomes and immunoproteasomes.15 Resistance to these
inhibitors is common, and new treatment strategies are
needed.16 Therefore, we selected a multiple myeloma cell
line for testing the validity of our “drug targeting through
enzyme inhibitor” scheme (Figure 1).
All cells contain constitutive proteasomes, while those of
myeloid lineage (including multiple myeloma cells) harbor
immunoproteasomes.17 We therefore selected our immuno-
proteasome-selective, covalent, irreversible proteasome inhib-
itor LU-035i (Figure 1, green fragment) as the targeting
agent.18 LU-035i has high selectivity for the chymotryptic sites
(β5i) of immunoproteasomes over the corresponding chymo-
tryptic sites (β5c) of constitutive proteasomes. This selectivity
is conferred by the cyclohexylalanyl moiety within the peptide
epoxyketone sequence. We have previously shown that
functionalization of the phenolic alcohol of the tyrosine
moiety in LU-035i does not affect immunoproteasome β5i
inhibition activity. For this reason, but also based on our
previous findings that β5i inhibition alone does not lead to cell
death (combined β5c/β5i inhibition is minimally required for
this),14 we selected this site in LU-035i for conjugation of the
cytotoxic agent. We elected to use a non-cytotoxic proteasome
inhibitor as our targeting device to allow for unambiguous
establishment whether release of toxic payload leads to cell
death. We selected doxorubicin as the cytotoxic agent due to
its clinical pedigree and the previously reported potential
clinical synergy with proteasome inhibition (for which in the
future broad-spectrum immunoproteasome inhibitors might be
utilized). Its use is limited by its severe side-effect profile,
particularly to cardiac tissue.19 Recent studies that demonstrate
synergistic effect of proteasome inhibitors and doxorubicin
when applied to tumor tissue further supported our conjugate
design.20 Furthermore, N-acylation renders doxorubicin
inactive (and non-toxic), allowing its use in targeting
conjugates.21
We here opted to link doxorubicin (Figure 1, red fragment
14) to LU-035i via two photolabile linkers: the oft-used bis-
functionalized 6-nitroveratryloxycarbonyl moiety22 and one
based on the recently reported 2-(4-nitrophenyl)benzofuran
chromophore (Figure 1, blue fragment, Scheme S1).23 The
latter was chosen for its favorable photochemical properties (ε
= 13 × 103 M−1 cm−1, λmax = 360 nm), its modest size, and its
compatibility with two-photon irradiation (δu = 20.7 GM at
740 nm) that allows deeper tissue penetration. Altogether this
led to the design of the two doxorubicin−LU-035i conjugates
1 and 2 (Figure 1, Scheme S2).
The synthesis of conjugate 1 (Scheme 1) was accomplished
in a convergent fashion to yield the product as a mixture of
stereoisomers, allowing for variation of both bio-active agents
as well as the nature of the linker moiety. (See SI for synthetic,
analytical, and data, as well as for the synthesis of peptide
epoxyketone 14 and conjugate 2.) Briefly, p-methoxyphenol 3
was converted into benzofuran 6, which was then lithiated
prior to treatment with triisopropylborate to yield boronic acid
7. Suzuki cross-coupling with aryl bromide 8 provided, after
desilylation (9 to 10), ketone reduction and reaction of the
generated phenolic OH with tert-butyl bromoacetate and then
trifluoroacetic acid, key photocage 11 amenable for function-
alization with two bio-active agents.
Conjugates 1 and 2 were next evaluated for their ability to
inhibit constitutive proteasome and immunoproteasome active
sites in live cells. To this end, AMO-1 cells, a human B cell
lymphoma cell line that expresses both proteasome subtypes,
were incubated with an increasing concentration of conjugates
1 and 2. Ensuing lysis and treatment with our set of three
activity-based proteasome probes that combined report on the
six active sites of constitutive proteasomes and immuno-
proteasomes16 (for structures, see Figure S3) and SDS-PAGE
resolution allows for detection of inhibited proteasome active
sites by fluorescence scanning of the wet gel slabs. As can be
seen (Figure 2A), both conjugates 1 effectively and selectively
block β5i (β5i IC50 = 0.53 μM, β5i/β5c = 18) and 2 (β5i IC50
= 0.42 μM, β5i/β5c = 21) and thus resemble the activity of the
parent compound, LU-035i (β5i IC50 = 0.37 μM, β5i/β5c =
500).18 Compounds 1 and 2 were shown to be cell penetrable,
with 90% of the maximum signal reduction of the targeted
proteasome subunit observed within 40 min of incubation
(Figures S1 and S2). At this time point, about equal inhibition
is observed of proteasomes in lysates and in living AMO-1 cells
(Figure S1).
With the aim to establish optimal photocleavage conditions
for releasing doxorubicin within cells following immuno-
proteasome β5i inhibition, we investigated the amount of
doxorubicin formed as a function of irradiation time (Figures
2B, S3, and S4). As much as 50% doxorubicin was released
when compound 1 was irradiated for 30 s at 375 nm (3 mW/
cm2), whereas 50 s of irradiation with 420 nm light (13 mW/
cm2) was required to yield the same percentage of the free
anthracycline. Quantitative release was observed after 1 min
irradiation of 1 at 375 nm and after 2 min irradiation at 420
nm. Construct 2 showed insufficient uncaging yields to warrant
further investigation (Figures S5 and S6). Phototoxicity studies
on cells exposed to either of the two wavelengths yielded a
Scheme 1. Synthesis of Conjugate 1a
aReagents and conditions: (a) bromoacetaldehyde diethyl acetal,
KOH, NMP, 70 °C, 15 h, 90%; (b) PPA, toluene, 111 °C, 16 h, 33%;
(c) (i) 1 M BBr3 in DCM, DCM, −78 °C (1 h)→ r.t. (1 h), 89%, (ii)
TBS-Cl, imidazole, DMF, 1 h, r.t., 70%; (d) (i) 1.6 M n-BuLi in
hexanes, THF, −78 °C, 1 h, (ii) triisopropyl borate, −78 °C (0.5 h)
→ r.t. (0.5 h); (e) 8, Pd(PPh3)4, K2CO3, THF/H2O, 75 °C, 18 h,
75%; (f) HF·pyridine, THF, r.t., 2 h, 93%; (g) (i) NaBH4, MeOH, 0
°C, 1 h, quant., (ii) tert-butyl bromoacetate, K2CO3, DMF, 70 °C, 3 h,
72%, (iii) TFA, DCM, r.t., 3 h, quant.; (h) 12, HCTU, DiPEA, DCM,
r.t. protected from UV, 18 h, quant.; (i) (i) N,N′-disuccinimidyl
carbonate, Et3N, DMF, (ii) 14, DMF, r.t., protected from UV, 59%.
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surprising result (Figures 2C and S7). Photolytic cell death
reached 50% after cells were exposed for 40 s to irradiation at
420 nm, while no significant decrease in cell viability was
observed after 180 s of irradiation at the higher energetic
wavelength (375 nm). We therefore conducted further
experiments at 375 nm to exclude phototoxic effects.
We next explored the ability of conjugate 1 to induce
apoptosis in AMO-1 cells, both those with an acquired
resistance for CFZ and CFZ-sensitive cells (Figures 2D and
S8). After incubation with conjugate 1, the cells were washed
and irradiated for 60 s at 375 nm. Three days later cell survival
was determined. Although CFZ-resistant AMO-1 cells
displayed minor resistance toward conjugate 1 when compared
to non-resistant AMO-1 cells, 50% of both cell variants were
killed when exposed to 5 μM of the compound after
irradiation.
As a control, we established that photocaged doxorubicin
without the proteasome-targeting moiety, combined with
irradiation, did not lead to significant cell death over
background (Figures S9−S11 depict the doxorubicin conjugate
46 we synthesized for this purpose as well as the doxorubicin
release as measured by LCMS and cytotoxicity assay). We also
assessed the toxicity of construct 1 in a cell line devoid of
immunoproteasome (HeLa S3). Pleasingly, no toxicity was
observed in this experiment over background either (Figure
S12).
If doxorubicin is released, compound 1 should induce DNA
double-stranded breaks, as assessed by γ-H2AX. Indeed,
irradiation of the cells induced γ-H2AX labeling as detected
by Western blots illustrating the release of active doxorubicin
by irradiation (Figure 2E).24
In conclusion, two probes that target the chymotrypsin-like
activity of immunoproteasomes have been synthesized and
used to deliver a cytotoxic payload to AMO-1 cells. One of the
conjugates (2) linked via an 6-nitroveratryloxycarbonyl did not
release the drug within a reasonable time frame. However, the
more photolabile NPBF-linked conjugate 1 yielded quantita-
tive release of the toxic payload after 1 min of irradiation at 375
nm, and after 2 min at 420 nm. Incubation with 1 followed by
irradiation with 375 nm light induced apoptosis in both regular
and CFZ-resistant AMO-1 cells in a concentration-dependent
manner. Based on these results, we believe that the combined
effect of proteolytic stress and poisoning topoisomerase II
yielding DNA damage may overcome the resistance that cells
can develop toward proteasome inhibitors. Although photo-
dynamic therapy with photosensitizers is already applied in
cancer therapy for esophageal and lung cancer,25 extending this
approach with new cytotoxic drug combinations and
alternative linkers may expand the clinical opportunities.
Finally, substitution of either of the two pharmacological
agents, for instance MMAE (a compound that cannot be used
systemically due to its high toxicity and that is often used in
antibody−drug conjugates)26 for doxorubicin, or the protea-
some inhibitor for other mechanism-based hydrolase inhib-
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